Precipio Signs Distribution Agreement For IV-Cell® and HemeScreen® in Japan
2024年1月18日 - 12:30AM
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO)
announces it has entered into an agreement with a Japanese
distributor for the sales and distribution of its products into the
Japanese market. The distributor has already secured its first
purchase order from a leading Japanese clinical laboratory, for
Precipio’s proprietary IV-Cell cytogenetics media. The first
shipment is expected to be delivered at the end of Q1-2024.
The Japanese
diagnostic market is renowned for its high level of quality and for
its intense scrutiny of products. Precipio was approached by a
Japanese laboratory with an inquiry about its IV-Cell media, and
entered into a testing period to evaluate the product.
The laboratory
conducted extensive testing of Precipio’s IV-Cell cytogenetics
media, including a comprehensive side-by-side analysis comparing it
to the current media used in their lab. The study, results of which
were shared with Precipio, demonstrated the superior performance of
IV-Cell, and ultimately resulted in their decision to adopt the
media in their laboratory.
The laboratory then
appointed a distributor to handle negotiations with Precipio,
resulting in a distribution agreement for its products within the
Japanese market. The parties have entered into a multiple year
commitment, with the intent of forming a long-term relationship to
leverage the distributor’s network within Japan to distribute
Precipio’s current, and future products, and bring diagnostic
advancements to a broad range of customers in the Japanese
market.
“There is no greater
demonstration of the quality and clinical utility of our product,
than its acceptance by a premier lab in Japan. I’m extremely proud
of our R&D team that has successfully created a product that
will be used in such a prestigious international market,” said Ilan
Danieli, Precipio’s CEO, “Furthermore, our entry into the Japanese
market underscores the effectiveness of our overseas sales &
marketing strategy. I expect that in 2024 we will also see
penetration into other markets globally, complementing our domestic
growth in the US market.”
About Precipio
Precipio is a healthcare biotechnology company
focused on cancer diagnostics. Our mission is to address the
pervasive problem of cancer misdiagnoses by developing solutions in
the form of diagnostic products and services. Our products and
services deliver higher accuracy, improved laboratory workflow, and
ultimately deliver better patient outcomes which reduce healthcare
expenses. Precipio develops innovative technologies in our clinical
laboratory where we design, test, validate, and run these products
intended to improve diagnostic outcomes. Precipio then
commercializes its technologies as proprietary products that serve
the global laboratory community and further scales Precipio’s reach
to eradicate misdiagnosis. For more information, please
visit www.precipiodx.com.
Please follow us on LinkedIn,
X@PrecipioDx and on Facebook.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. All statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements, including, without
limitation, statements regarding the targets set herein and related
timing.
Except for historical information, statements
about future volumes, sales, growth, costs, cost savings, margins,
earnings, earnings per share, diluted earnings per share, cash
flows, plans, objectives, expectations, growth or profitability are
forward-looking statements based on management’s estimates,
beliefs, assumptions and projections. Words such as “could,” “may,”
“expects,” “anticipates,” “will,” “targets,” “goals,” “projects,”
“intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,”
and variations on such words, and similar expressions that reflect
our current views with respect to future events and operational,
economic and financial performance, are intended to identify such
forward-looking statements. These forward-looking statements are
only predictions based on management’s current expectations. These
statements are neither promises nor guarantees, but involve known
and unknown risks, uncertainties and other important factors that
may cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including, but not limited to, the important factors
discussed under the caption “Risk Factors” in our Annual Report on
Form 10-K for the fiscal year ended December 31, 2022 and our other
reports filed with the U.S. Securities and Exchange Commission. Any
such forward-looking statements represent management’s estimates as
of the date of this press release only. While we may elect to
update such forward-looking statements at some point in the future,
except as required by law, we disclaim any obligation to do so,
even if subsequent events cause our views to change. These
forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of
this press release.
Inquiries:
investors@precipiodx.com
+1-203-787-7888 Ext. 523
Precipio (NASDAQ:PRPO)
過去 株価チャート
から 8 2024 まで 9 2024
Precipio (NASDAQ:PRPO)
過去 株価チャート
から 9 2023 まで 9 2024